Leads to Development (L2D) is a privately owned organisation formed in 2009 as a high-value service company that supports clients developing innovative therapies. Based in Paris, France, L2D’s international team provides hands-on scientific, regulatory and project management expertise across all stages of drug development.
Historically, L2D’s core expertise centred on CMC and nonclinical aspects of drug development, primarily focused on the earlier stages, from discovery to the first tests in humans. Today, we support our clients throughout their entire development programmes, up to market application, and offer a widened range of services, including clinical trial oversight. Our know-how spans multiple indications and therapeutic product classes, from small molecules to peptides, biologics and implantable medical devices.